Updated results of a first-in-human, Phase Ⅰa/Ⅰb study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Gang An, Baijun Fang, Xiaobing Huang, Yan Xu, Fei Li, Zhen Cai, Xiaojing Yan, Xianqi Feng, Wuping Li, Xiangmin Tong, Zengjun Li, Yuzhang Liu, Feifei Che, Xin'ai Yang, Xianlin Duan, Peng Shao, Xiaoyan Kang, Lugui Qiu
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Zhengzhou University, Henan Cancer Hospital, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, First Affiliated Hospital of Nanchang University, First Affiliated Hospital Zhejiang University, Zhejiang University, First Hospital of China Medical University, China Medical University, Qingdao University, Affiliated Hospital of Qingdao University, Jiangxi Provincial Cancer Hospital, Westlake University, Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Shandong Tumor Hospital, Shandong First Medical University, Qilu Pharmaceutical Co., Ltd. (China)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108474021
Cites:
Cited by:
Related to: